Encarnacion Sastre nackt sorted by
relevance

Admin07.08.2021

Encarnación Sastre

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 tribe study.
102
Admin19.07.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Loupakis F, Cremolini C, Masi G, et al.
8307
Admin05.08.2021

Encarnación Sastre

error "Either a producer id or custom logger must be defined" ;this.
2301
Admin13.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

16 Hospital Universitario de Donostia, Medical Oncology Department, San Sebastian, Spain.
6506
Admin11.06.2021

Encarnación Sastre

.
6701
Admin19.06.2021

Encarnación Sastre

PMID: 33738696 Free PMC article.
1809
Admin03.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

MJS has done consulting or advisory roles for Amgen, Merck, Roche, Sanofi and Servier, and received travel, accommodation, and expenses from Amgen, Merck and Roche.
6403
Admin27.08.2021

Encarnación Sastre

11 Hospital Universitario Virgen de las Nieves, Medical Oncology Department, Granada, Spain.
8909
Admin21.06.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

9 Hospital Universitario Lucus Augusti, Medical Oncology Department, Lugo, Spain.
Admin29.07.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

2 Hospital Universitario Central de Asturias, Medical Oncology Department, Oviedo, Spain.
3808